Research published at ASCO 2024 together with the World Lung Conference (phase III CROWN trial) demonstrated that treatment-naïve patients with ALK-positive stage IIIB/IV NSCLC received either crizotinib or lorlatinib out of 296 participants [16,17]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.